ライフサイエンスコーパス: respiratory failure

1 oints [CI, 2.5 to 4.8 percentage points] for respiratory failure).

2 domized Evaluation of Sedation Titration for Respiratory Failure).

3 tic lung remodeling that often culminates in respiratory failure.

4 ase, causing muscle paralysis and death from respiratory failure.

5 unocompromised patients with hypoxemic acute respiratory failure.

6 te myocardial infarction, heart failure, and respiratory failure.

7 essure use in a monitored setting to prevent respiratory failure.

8 used to sustain life in patients with acute respiratory failure.

9 2%) was the main etiology of acute hypoxemic respiratory failure.

10 l hospitals were de novo listed during acute respiratory failure.

11 risk of death in hematological patients with respiratory failure.

12 d to grade 5 cardiac failure); one had fatal respiratory failure.

13 The presence of VIDD impedes recovery from respiratory failure.

14 have examined outcomes of P-ECMO for severe respiratory failure.

15 r preventing reintubation and postextubation respiratory failure.

16 for selected patients with acute hypoxaemic respiratory failure.

17 ents and is associated with severe hypoxemic respiratory failure.

18 Both individuals died at 5 months after respiratory failure.

19 g technique increasingly used to treat acute respiratory failure.

20 improve the outcomes of patients with acute respiratory failure.

21 neumonia to a primary diagnosis of sepsis or respiratory failure.

22 tracorporeal membrane oxygenation for severe respiratory failure.

23 l benefits in unselected patients with acute respiratory failure.

24 ction often developed severe disease causing respiratory failure.

25 nged from mild upper respiratory symptoms to respiratory failure.

26 scillatory ventilation for pediatric hypoxic respiratory failure.

27 ated with increased mortality in adults with respiratory failure.

28 unocompromised patients with hypoxemic acute respiratory failure.

29 on is a lifesaving measure for patients with respiratory failure.

30 improved clinical outcomes in patients with respiratory failure.

31 is a serious lung disorder that can lead to respiratory failure.

32 eady decline of lung function and ultimately respiratory failure.

33 ng unit, or who had a tracheostomy for acute respiratory failure.

34 d drop and can be fatal due to neuromuscular respiratory failure.

35 racterized by a progressive and irreversible respiratory failure.

36 ight and weight and mild chronic restrictive respiratory failure.

37 ict survival for patients receiving ECMO for respiratory failure.

38 treating influenza patients hospitalized for respiratory failure.

39 d for greater than 3 days after the onset of respiratory failure.

40 monia and a principal diagnosis of sepsis or respiratory failure.

41 lation can trigger lung injury and sometimes respiratory failure.

42 ge were not conducted because of progressive respiratory failure.

43 ns and presented with acute severe hypoxemic respiratory failure.

44 sulfation was suppressed in all groups with respiratory failure.

45 including a principal diagnosis of sepsis or respiratory failure.

46 eatment with antitoxin, some patients suffer respiratory failure.

47 y or noninvasive ventilation) in adults with respiratory failure.

48 poreal membrane oxygenation for severe acute respiratory failure.

49 available for children at risk of death from respiratory failure.

50 xtracorporeal membrane oxygenation for acute respiratory failure.

51 fort in adult patients recovering from acute respiratory failure.

52 rized by repeated lung infections leading to respiratory failure.

53 volution toward pleuropulmonary fibrosis and respiratory failure.

54 nous extracorporeal membrane oxygenation for respiratory failure.

55 are used in adults with or at risk of acute respiratory failure.

56 ive sleep apnea syndrome, or other causes of respiratory failure.

57 nit, or 3) received a tracheostomy for acute respiratory failure.

58 la is increasingly used in the management of respiratory failure.

59 ane oxygenation initiation for children with respiratory failure.

60 nous extracorporeal membrane oxygenation for respiratory failure.

61 unique differences in the patterns of cardio-respiratory failure.

62 nous extracorporeal membrane oxygenation for respiratory failure.

63 unocompromised patients with hypoxemic acute respiratory failure.

64 tion during mechanical ventilation for acute respiratory failure.

65 ing greater mobility levels in patients with respiratory failure.

66 ion, pulmonary or systemic hypertension, and respiratory failure.

67 ities known to precipitate acute hypercapnic respiratory failure.

68 were diarrhoea (10 [5%], 15 [7%], 14 [7%]), respiratory failure (11 [5%], 14 [7%], 11 [5%]), and con

69 treatment (pulmonary embolism [200 mg/day], respiratory failure [120 mg/day], haemoptysis [80 mg/day

70 mia (14 [6%]; one related to treatment), and respiratory failure (14 [6%]).

71 open heart surgery (0.2%), and postoperative respiratory failure (2.4%).

72 nous extracorporeal membrane oxygenation for respiratory failure, 2) veno-arterial extracorporeal mem

73 Top diagnostic categories: sepsis (47%) and respiratory failure (22%).

74 3 [74.0% reduction]; P < .001 for trend) and respiratory failure (29.9 PACs placed per 1000 admission

75 aphic progression, [2] persistence of severe respiratory failure, [3] development of shock, [4] need

76 There was a high prevalence of respiratory failure (39.8%) and the presence of a centra

77 %), cardiogenic shock (0.5%-1.5%), and acute respiratory failure (4.3%-20.8%) from 2001 through 2012.

78 ute respiratory failure) or to prevent acute respiratory failure (5.3% vs 8.3%; risk ratio=0.64 [0.46

79 ncluded bacterial pulmonary infections (8%), respiratory failure (7%), sepsis or septic shock (5%), a

80 e recoded all eligible patients to sepsis or respiratory failure, 90 hospitals (95% CI, 84-95) improv

81 missions (n = 524; 50%) were marked by acute respiratory failure, acute kidney injury, or sepsis.

82 anifestation of Guillain-Barre syndrome with respiratory failure affects 20-30% of cases.

83 tion in patients who develop hypoxemic acute respiratory failure after abdominal surgery.

84 ailed extubation) or were deemed at risk for respiratory failure after extubation due to preexisting

85 f nonintubated patients with acute hypoxemic respiratory failure (AHRF).

86 without hypercapnia who had acute hypoxemic respiratory failure and a ratio of the partial pressure

87 NTS/Critically ill obese patients with acute respiratory failure and anesthetized swine.

88 to death occurred in four (2%) patients (one respiratory failure and circulatory collapse [possibly r

89 MERS-CoV causes severe acute hypoxemic respiratory failure and considerable extrapulmonary orga

90 lung disease of unknown cause that leads to respiratory failure and death within 5 years of diagnosi

91 ance, disrupted gas exchange, and ultimately respiratory failure and death.

92 ular infiltration in lungs, often leading to respiratory failure and death.

93 nous extracorporeal membrane oxygenation for respiratory failure and extracorporeal cardiopulmonary r

94 In adults, physiologic signatures of respiratory failure and hemorrhage were distinct from ea

95 Patients with severe hypoxic respiratory failure and immunocompromise had the highest

96 sive motor neuron manifestations, death from respiratory failure and infections in infantiles.

97 Persistence of bacteremia, shock, respiratory failure and intensive care unit admission we

98 h occurred in a 59-year-old woman with acute respiratory failure and mean pulmonary artery pressure o

99 nt and derecruitment of atelectasis in acute respiratory failure and might harm brain tissue integrit

100 progressive muscle weakness, cardiomyopathy, respiratory failure and neurocognitive impairment.

101 ion of phrenic motor neurons that results in respiratory failure and perinatal lethality in mice.

102 of this spectrum may present with hypoxemic respiratory failure and pulmonary infiltrates, meeting c

103 nferior to NIV for preventing postextubation respiratory failure and reintubation in patients at high

104 ht play an important role in the etiology of respiratory failure and repair.

105 eal CO2 removal in patients with hypercapnic respiratory failure and respiratory acidosis nonresponsi

106 oded with a principal diagnosis of sepsis or respiratory failure and risk-standardized mortality rate

107 with extracorporeal membrane oxygenation for respiratory failure and sepsis between the service being

108 oxygenation treatment in adult patients with respiratory failure and sepsis can be lifesaving in appr

109 orporeal membrane oxygenation in adults with respiratory failure and sepsis is steadily increasing, b

110 [5%]); the most common causes of death were respiratory failure and septic shock.

111 examine its applicability to trials of acute respiratory failure and severe sepsis.

112 an pediatric intensive care units with acute respiratory failure and suspected influenza virus infect

113 deaths were noted in chart review--one from respiratory failure and the second of unknown pathogenes

114 e neurodegenerative disorder, which leads to respiratory failure and usually death during childhood.

115 ng adult survivors of critical illness after respiratory failure and/or shock from three Veterans Aff

116 t study of intensive care unit patients with respiratory failure and/or shock, we examined the associ

117 One death occurred in the A1PI group (respiratory failure) and three occurred in the placebo g

118 (14%) required intensive care, 359 (5%) had respiratory failure, and 40 (1%) died.

119 ere hospitalized, 125 (90%) had pneumonia or respiratory failure, and 65 of 103 with available data (

120 coronary syndrome, 22.9% postsurgery, 13.3% respiratory failure, and 8.4% ventricular fibrillation.

121 sive ventilation for de novo acute hypoxemic respiratory failure, and a high expired tidal volume is

122 attributed to treatment (pneumonitis, acute respiratory failure, and cardiovascular failure).

123 pulmonary architecture, leading to hypoxia, respiratory failure, and death.

124 umerous complications, including septicemia, respiratory failure, and encephalopathy.

125 Acute kidney injury, acute respiratory failure, and new-onset subclinical atrial fi

126 Advanced age, acute respiratory failure, and sepsis were the strongest predi

127 survival differences between BLS and ALS for respiratory failure, and showed better survival at all t

128 itis, herpes dermatitis, multiple fractures, respiratory failure, and transient ischaemic attack) and

129 ergic syndrome with decreased consciousness, respiratory failure, and, in the case of insecticides, a

130 Diaphragmatic weakness and acute respiratory failure are common in sepsis.

131 o intensive care unit (ICU) because of acute respiratory failure (ARF) has not been determined to dat

132 membrane oxygenation (ECMO) for severe acute respiratory failure (ARF) in adults is growing rapidly g

133 RATIONALE: Research evaluating acute respiratory failure (ARF) survivors' outcomes after hosp

134 ictors of mortality with postoperative acute respiratory failure associated with improved survival.

135 tive adults with either sepsis or trauma and respiratory failure at 14 university intensive care unit

136 otic dehiscence, wound infection, noncardiac respiratory failure, atrial fibrillation, congestive hea

137 a was associated with an increased chance of respiratory failure before (16 [36.4%] of 44, P = .001)

138 -11.3; OR, 6.7; 95% CI, 2.1-21.1), and acute respiratory failure (beta coefficient, 6.2; 95% CI, 5.1-

139 ting outcomes for patients with severe acute respiratory failure but do not predict whether ECMO will

140 creasingly applied to prevent or treat acute respiratory failure, but its benefit on survival is stil

141 Acute respiratory failure, by central and peripheral mechanism

142 Respiratory failure causes death in SMA but the underlyi

143 of patients transferred to a regional severe respiratory failure center that routinely employs admiss

144 Tertiary referral severe respiratory failure center, university teaching hospital

145 domized Evaluation of Sedation Titration for Respiratory Failure clinical trial, a pediatric multicen

146 domized Evaluation of Sedation Titration for Respiratory Failure clinical trial.

147 By assigning sepsis and respiratory failure codes more liberally, hospitals migh

148 healthy donors as well as from subjects with respiratory failure due to altered mental status (intoxi

149 utcomes included time to recovery from acute respiratory failure, duration of weaning from mechanical

150 Acute kidney injury and acute respiratory failure each occurred in 30% of admissions.

151 nts admitted to the ICU with hypoxemic acute respiratory failure, early noninvasive ventilation compa

152 n of patients surviving an acute hypercapnic respiratory failure episode requiring admission to the i

153 ngs have important implications for neonatal respiratory failure, especially when maternal bile acids

154 Acute respiratory failure etiologies were mostly pneumonia (n

155 domized Evaluation of Sedation Titration for Respiratory Failure extubation readiness test) in predic

156 mon, were included when they developed acute respiratory failure (failure of a spontaneous breathing

157 Death ensued from respiratory failure, followed by terminal asystole.

158 Among patients with hypoxemic respiratory failure following abdominal surgery, use of

159 ars) patients who required P-ECMO for severe respiratory failure from 1989 to 2013 were extracted fro

160 successful extubation in children with acute respiratory failure from lower respiratory tract disease

161 In children with acute respiratory failure from lower respiratory tract disease

162 reatment site recorded in nine patients, and respiratory failure (grade 4) noted in two patients.

163 nous extracorporeal membrane oxygenation for respiratory failure had neurologic injury.

164 y, whereas patients with postoperative acute respiratory failure had the best survival rate.

165 Respiratory failure has the highest incidence in the ear

166 nts with interstitial lung disease and acute respiratory failure have a poor prognosis especially if

167 ry ventilation (HFOV) in children with acute respiratory failure have not been established.

168 rrespective of initial values, also presaged respiratory failure (hazard ratio, 7.2; 95% confidence i

169 cute kidney injury, cardiac surgery, anemia, respiratory failure, heart failure, cardiac arrest, meta

170 unocompromised patients with hypoxemic acute respiratory failure, high-flow nasal oxygen when compare

171 sive ventilation for de novo acute hypoxemic respiratory failure (i.e., not due to exacerbation of ch

172 The main reason for ICU admission was acute respiratory failure in 111 patients (81.6%), of whom 89

173 y resuscitation in 877 patients (19.4%), and respiratory failure in 640 patients (14.1%), respectivel

174 ncy oscillatory ventilation (HFOV) for acute respiratory failure in children is prevalent despite the

175 ess syndrome (ARDS) remains a major cause of respiratory failure in critically ill patients.

176 Acute respiratory failure in hematological patients is related

177 They explain respiratory failure in infants with congenital pulmonary

178 Further analysis revealed increased respiratory failure in nonsurvivors.

179 in one patient, and acute renal failure and respiratory failure in one patient) were suspected to be

180 muscle stiffness, rather than weakness, and respiratory failure in one patient.

181 on lymphatic function may also contribute to respiratory failure in premature infants.

182 vasive or noninvasive) for acute hypercapnic respiratory failure in the ICU.

183 mortality rate among patients with hypoxemic respiratory failure in the intervention arm (8/8, 100%)

184 ts except for higher cardiac arrhythmias and respiratory failure in the non-PPCMP in the first 3 mont

185 cter of mobility for ICU patients with acute respiratory failure in U.S.

186 Theoretical advantages of ECLS for respiratory failure include the ability to rest the lung

187 In 217 children with acute hypoxemic respiratory failure, initial end-tidal alveolar dead spa

188 dmission to an intensive care unit involving respiratory failure, intubation, and mechanical ventilat

189 In immunocompromised patients with acute respiratory failure, invasive mechanical ventilation rem

190 FOV compared with CMV in children with acute respiratory failure is associated with worse outcomes.

191 tracorporeal membrane oxygenation for severe respiratory failure is clinically significant, and routi

192 dministered in patients with acute hypoxemic respiratory failure is debated.

193 embrane oxygenation for patients with severe respiratory failure is increasingly common.

194 tracheal aspirates from preterm infants with respiratory failure is predictive of the development of

195 Clinicians identified 1,206 episodes of respiratory failure leading to urgent unplanned intubati

196 In patients recovering from acute respiratory failure, levels of neurally adjusted ventila

197 Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE) was an international, mu

198 Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE).

199 use of the principal diagnosis of sepsis or respiratory failure may bias efforts to compare hospital

200 breathing, nonintubated patients with acute respiratory failure may have a high respiratory drive an

201 ured by Medical Research Council sum score), respiratory failure (measured by requirement and duratio

202 the other to disease-related complications (respiratory failure, myositis, and an acute coronary eve

203 momelotinib (acute myeloid leukaemia [n=2], respiratory failure [n=2, with one considered possibly r

204 4.48; 95% CI, 3.69-56.86; P < .001), and new respiratory failure necessitating tracheostomy (OR, 23.9

205 e [7%] cerebrovascular accident and one [7%] respiratory failure); neither of these deaths were consi

206 1 Mb Nxf2-Nxf3 X-chromosomal segment exhibit respiratory failure, neonatal lethality and cleft palate

207 In patients with concomitant respiratory failure, noninvasive ventilation represents

208 One death due to respiratory failure occurred in the cabozantinib group,

209 day increase; 95% CI, 0.3-0.5), and risk for respiratory failure (odds ratio, 1.5; 95% CI, 1.2-1.7) a

210 vasive ventilation outside the ICU for acute respiratory failure of heterogeneous causes and to ident

211 uctive pulmonary disease exacerbation, acute respiratory failure of mixed etiologies, and postoperati

212 o group), dyspnoea (three [1%] vs two [1%]); respiratory failure (one [<1%] vs three [2%]), myocardia

213 e code for pneumonia and secondary codes for respiratory failure or acute organ dysfunction.

214 study who survived a critical illness due to respiratory failure or shock were evaluated for global c

215 ntre cohort study, we enrolled patients with respiratory failure or shock who were undergoing treatme

216 ical and surgical ICU patients admitted with respiratory failure or shock.

217 of mixed etiologies, and postoperative acute respiratory failure) or to prevent acute respiratory fai

218 oded with a principal diagnosis of sepsis or respiratory failure, outlier status under the broader de

219 piratory infection had more severe hypoxemic respiratory failure (PaO2/FIO2: 106 [66, 160] vs 176 [10

220 ne abdominal surgery and developed hypoxemic respiratory failure (partial oxygen pressure <60 mm Hg o

221 domized Evaluation of Sedation Titration for Respiratory Failure patients (5%) with moderate/severe p

222 In acute respiratory failure patients undergoing pressure support

223 In a cohort of hospitals caring for acute respiratory failure patients, physical therapy/occupatio

224 ates the hypothesis that in ventilated acute respiratory failure patients, Sigh may enhance regional

225 Respiratory failure, persistent ventricular tachycardia,

226 respiratory syncytial virus, sepsis-induced respiratory failure, pertussis, and "other"; and preextr

227 al analgesia did not affect the incidence of respiratory failure, pneumonia, anastomotic leak, ileus,

228 disorder that leads to lung destruction and respiratory failure primarily in women.

229 DR, and HMOX1 were associated with prolonged respiratory failure, prolonged hospitalization, extensiv

230 domized Evaluation of Sedation Titration for Respiratory Failure protocol, usual care extracorporeal

231 domized Evaluation of Sedation Titration for Respiratory Failure protocol.

232 domized Evaluation of Sedation Titration for Respiratory Failure protocol.

233 nts with interstitial lung disease and acute respiratory failure provided they are candidates for lun

234 admission, need for mechanical ventilation, respiratory failure, pulmonary embolism, sepsis, or deat

235 ng in-hospital mortality among children with respiratory failure receiving extracorporeal membrane ox

236 jor postoperative respiratory complications (respiratory failure, reintubation, pulmonary edema, and

237 extracorporeal membrane oxygenation run for respiratory failure reported to the Extracorporeal Life

238 Severe hypercapnic respiratory failure requiring ICU admission resulted pri

239 ; women, 55%) admitted to the ICU with acute respiratory failure requiring mechanical ventilation wer

240 Adult patients (>/= 18 yr old) with acute respiratory failure requiring mechanical ventilation.

241 onchial mucosa, which may be associated with respiratory failure requiring mechanical ventilation.

242 had progressive neurologic deterioration and respiratory failure, requiring intensive care unit admis

243 Secondary outcomes included postextubation respiratory failure, respiratory infection, sepsis and m

244 Severe H1N1 pneumonia with acute respiratory failure results in infiltration of lungs due

245 Risk factors for respiratory failure (RF) and mortality due to RSV were a

246 SUMMARY BACKGROUND DATA: Postoperative respiratory failure (RF), defined as ventilator dependen

247 This study aims to develop a Respiratory Failure Risk Score (RFRS) with good predicta

248 in the NIV group experienced postextubation respiratory failure (risk difference, 12.9%; 95% CI, 6.6

249 patients died in follow-up from hypercapnic respiratory failure secondary to neuromuscular weakness.

250 Despite this approach, death from respiratory failure secondary to the development and pro

251 e potentially catastrophic illnesses such as respiratory failure, sepsis, and hemorrhage that present

252 Surviving acute hypercapnic respiratory failure should be an opportunity to systemat

253 Among patients hospitalized with acute respiratory failure, SRT compared with usual care did no

254 domized Evaluation of Sedation Titration for Respiratory Failure study tested the effect of a nurse-l

255 Understand the Global Impact of Severe Acute Respiratory Failure) study described the management of p

256 domized Evaluation of Sedation Titration for Respiratory Failure) study, a prospective cluster random

257 d mobilization goals for patients with acute respiratory failure supported by venovenous extracorpore

258 rch studies evaluating the outcomes of acute respiratory failure survivors after hospital discharge.

259 l clinical research studies evaluating acute respiratory failure survivors after hospital discharge.

260 2) results from a qualitative study of acute respiratory failure survivors' outcomes after hospital d

261 from surveys of clinical researchers, acute respiratory failure survivors, and caregivers that rated

262 h evaluating postdischarge outcomes of acute respiratory failure survivors: clinical researchers, cli

263 cebo group (16 [11%]), mainly as a result of respiratory failure (ten [7%] vs five [3%]).

264 yndrome (ARDS) is a form of severe hypoxemic respiratory failure that is characterized by inflammator

265 rophic lateral sclerosis (ALS), end life via respiratory failure, the ability to harness respiratory

266 undergoing mechanical ventilation for acute respiratory failure, the use of a sedation protocol comp

267 horacic surgery patients with or at risk for respiratory failure, the use of high-flow nasal oxygen t

268 nts hospitalized for influenza virus-induced respiratory failure, there is an urgent need for new the

269 ents with a principal diagnosis of sepsis or respiratory failure, this rate was better than the mean

270 Adult patients with severe acute respiratory failure treated by ECMO from 2000 to 2012 we

271 tubation was detected in patients with acute respiratory failure treated with high-flow nasal cannula

272 unocompromised patients with hypoxemic acute respiratory failure treated with high-flow nasal oxygen.

273 Six (15%) developed acute respiratory failure treated with invasive mechanical ven

274 nts with interstitial lung disease and acute respiratory failure treated with or without ECMO from Ma

275 patients with nonhypercapnic acute hypoxemic respiratory failure, treatment with high-flow oxygen, st

276 admitted for an episode of acute hypercapnic respiratory failure underwent an assessment of lung, car

277 sed in the treatment of patients with severe respiratory failure until organ recovery and as a bridge

278 harge, length of stay, mortality, pneumonia, respiratory failure, urinary tract infection, urinary re

279 Prolonged ECMO use for adult respiratory failure was associated with a lower (45.4%)

280 days among patients with trauma, stroke, and respiratory failure was higher with BLS than ALS (6.1 pe

281 Postextubation respiratory failure was less common in the high-flow gro

282 veloped ARDS in the first 48 hours and whose respiratory failure was managed with invasive mechanical

283 d to be related to everolimus treatment, but respiratory failure was suspected to be related.

284 Respiratory failure was the most common serious adverse

285 Sepsis, acute kidney injury, and acute respiratory failure were associated with mortality.

286 17 years) mechanically ventilated for acute respiratory failure were enrolled in 2009-2013 and follo

287 atients with severe H1N1 pneumonia and acute respiratory failure were enrolled.

288 eferred to our intensive care unit for acute respiratory failure were included in the analysis.

289 Patients eligible for recoding to sepsis or respiratory failure were those with a principal Internat

290 for acute, potentially reversible cardiac or respiratory failure, when conventional therapy has been

291 -deficient newborns die from atelectasis and respiratory failure, which can be mitigated by in utero

292 Hyperoxia can exacerbate acute respiratory failure, which has high mortality and no spe

293 on and a 42% (95% CI, 10-85%) higher rate of respiratory failure while awaiting lung transplantation.

294 ransplantation and higher rates of death and respiratory failure while awaiting transplantation.

295 ary hypertension, and severe acute hypoxemic respiratory failure who underwent endotracheal intubatio

296 may progress to acute lung injury (ALI) and respiratory failure with a potentially fatal outcome.

297 uences range from subclinical pneumonitis to respiratory failure, with fibrosis development in some p

298 , unrelenting lung scarring, with death from respiratory failure within 2-4 years unless lung transpl

299 utcomes were reintubation and postextubation respiratory failure within 72 hours.

300 myocardial injury, stroke, renal failure, or respiratory failure) within 30 days, both analysed by in